scispace - formally typeset
R

Roger S. Flugel

Researcher at Harvard University

Publications -  13
Citations -  1234

Roger S. Flugel is an academic researcher from Harvard University. The author has contributed to research in topics: Solifenacin & Overactive bladder. The author has an hindex of 7, co-authored 13 publications receiving 1182 citations. Previous affiliations of Roger S. Flugel include Massachusetts Institute of Technology.

Papers
More filters
Journal ArticleDOI

A new enzyme superfamily — the phosphopantetheinyl transferases

TL;DR: This work has identified a large family of proteins having 12-22 % similarity with ACPS, which are putative P-pant transferases, and found three of these proteins, E. coli EntD and o195, and subtilis Sfp, have been overproduced, purified and found to have P- pant transferase activity.
Journal ArticleDOI

Post-translational modification of polyketide and nonribosomal peptide synthases.

TL;DR: Phosphopantetheinyl transferases required for fatty acid, peptide and siderophore biosynthesis have been characterized and a consensus sequence noted in order to facilitate future identification of additional proteins catalyzing phosphopantethinyl transfer.
Journal ArticleDOI

Holo-(acyl carrier protein) synthase and phosphopantetheinyl transfer in Escherichia coli.

TL;DR: It is shown that a conditional acpS mutant accumulates apoACPin vivo under nonpermissive conditions in a manner similar to the E. coli MP4 strain, and it is demonstrated that the gene product, YhhU, of a previously identified E. Escherichia coli open reading frame can completely suppress theacpS conditional, lethal phenotype upon overexpression of the protein.
Journal ArticleDOI

Melting of phospholipid tubules.

TL;DR: The melting of lipid-based microcylinders (tubules) has been investigated for systems with single and multiple bilayer walls using high field, magnetic birefringence, and precision microcalorimetry.
Patent

Methods of improving quality of sleep

TL;DR: In this paper, a combination of antimuscarinic or anticholinergic agent and muscarinic agonist for the treatment of poor quality of sleep in the OAB patient was presented.